Connable Office Inc’s Myriad Genetics MYGN Stock Holding History

Connable Office Inc’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,627	Closed	-$183K	–	215
2022 Q4	$183K	Hold	12,627	–	–	0.03%	197
2022 Q3	$241K	Sell	12,627 -1,102	-8%	-$25.3K	0.04%	175
2022 Q2	$249K	Hold	13,729	–	–	0.04%	183
2022 Q1	$346K	Hold	13,729	–	–	0.05%	164
2021 Q4	$379K	Buy	13,729 +1,101	+9%	+$31.9K	0.05%	168
2021 Q3	$408K	Hold	12,628	–	–	0.06%	143
2021 Q2	$386K	Sell	12,628 -7,338	-37%	-$212K	0.05%	147
2021 Q1	$608K	Hold	19,966	–	–	0.09%	118
2020 Q4	$395K	Buy	19,966 +5,512	+38%	+$89K	0.06%	150
2020 Q3	$188K	Buy	14,454 +387	+3%	+$4.9K	0.04%	181
2020 Q2	$160K	Buy	14,067 +1,477	+12%	+$21K	0.03%	177
2020 Q1	$180K	Hold	12,590	–	–	0.04%	139
2019 Q4	$343K	Hold	12,590	–	–	0.06%	134
2019 Q3	$360K	Buy	+12,590	New	+$367K	0.06%	120

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Connable Office Inc's MYGN Position: Q1 2023 in Review

Connable Office Inc sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 12,627 shares — an estimated $183K sold.

Connable Office Inc first reported a position in MYGN in Q3 2019 and held it in 14 quarters. The position peaked at $608K in Q1 2021. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

Connable Office Inc reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
Connable Office Inc sold 12,627 Myriad Genetics shares in Q1 2023, an estimated $183K.
Connable Office Inc first reported a position in Myriad Genetics in Q3 2019 and held it in 14 quarters.
Connable Office Inc's Myriad Genetics position peaked at $608K in Q1 2021.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on Connable Office Inc's 13F filing for Q1 2023, filed 17 Apr 2023.